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Abstract
Background: Osteoarthritis (OA) is the most prevalent chronic joint disease, characterized by joint structural
deterioration, pain and loss of function among the elders. It is also associated with several extra-articular symptoms
(fatigue, sleep disorders, anxiety and depression) and a reduction of life quality. Studies have revealed that patients
with OA benefitted from enhanced management via telemedicine. Guangdong Online Hospital (GOH) is the first
officially recognized web-based hospital that provides telemedicine service in China. However, the effective
implementation of GOH telemedicine (GOHT) to enhance management for patients with OA remains unknown.
Methods/design: An assessor-blinded, parallel randomized controlled trial will be performed to study the feasibility
and effectiveness of GOHT in the enhanced management of OA. Forty participants with knee OA will be recruited for a
6-month study. Patients meeting the inclusion criteria will be randomly allocated to receive conventional therapy (CT)
or conventional therapy plus a brief GOH-based intervention (CT-GOHT). The primary outcome is the feasibility of a full-
scale randomized controlled trial. The secondary outcomes include the self-reported total score of the Western Ontario
and McMaster Universities Osteoarthritis Index (WOMAC), the Multidimensional Fatigue Inventory (MFI), the Pittsburgh
Sleep Quality Index (PSQI) and the Hospital Anxiety and Depression Scale (HADS). Assessments will be performed at
baseline, 2 weeks, 3 months and 6 months later after the initiation of the study.
Discussion: This trial is intended to test the application of GOHT in the chronic management in knee OA. The hypothesis
is that OA patients may receive disease management via this network platform conveniently and effectively, especially
those in the remote areas of our country. GOHT telemedicine would be an attractive alternative to traditional methods
for disease management in knee OA. The results could provide preliminary experiences and guidance for an upcoming
full-scale randomized controlled trial (RCT) in disease management via telemedicine.
Trial registration: ChiCTR: ChiCTR1800014465. Registered on 16 January 2018.
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Background
Osteoarthritis (OA) is a degenerative joint disease that
involves the whole joint structure, including synovium,
cartilage, menisci, ligaments, periarticular muscle, capsule
and subchondral bone [1]. Globally, the age-adjusted
prevalence of knee OA is 3.8% and of hip OA is 0.85% [2].
In China, the prevalence of symptomatic knee OA among
people aged 45 years or older is 10.3% in women and 5.7%
in men [3]. OA causes joint pain, functional impairment
and disability [4]. Moreover, OA patients suffer from a
series of extra-articular symptoms. It is reported that poor
sleep is highly prevalent in OA patients and approximately
40% of OA patients have substantial fatigue which is
related to pain, sleep disturbance and depressed mood
[5, 6]. Besides, a considerable number of OA patients
experience clinically significant depression and anxiety
[7, 8]. OA has become a very serious medical problem
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that significantly decreases the quality of patients’ life
and causes large social and economic burden [9].
As a prevalent chronic disease, OA patients are in
need of long-term disease management to improve their
quality of life and to prevent disability, and this demand
is expected to increase greatly in the coming years with
the rising incidence. As an emerging concept in health
care, telemedicine, provides ways to remotely deliver
consultations, treatments and monitoring disease activ-
ities [10]. Telemedicine has been shown positive results
in feasibility, effectiveness and patient satisfaction in the
use of chronic disease management [11, 12]. Evidence
has shown that Internet-based interventions significantly
improve health status and meet with high acceptance
and high user satisfaction in patients with OA [13].
As an institution of Guangdong Second Provincial
General Hospital, Guangdong Online Hospital (GOH) is
China’s first officially recognized online hospital. Clini-
cians of almost all medical departments are available at
this online platform (http://www.youdeyi.com/). Patients
are able to receive online health services such as consul-
tations, disease education and preliminary treatment
suggestions through the telemedicine platforms with
audio and video settings in the communities around the
province. Our previous study has demonstrated that
GOH provided a convenient platform for ankylosing
spondylitis patients to receive effective disease manage-
ment, especially those in the remote areas of the country
[14]. The positive results encourage us to explore the
role of GOHT telemedicine in the management of OA.
Therefore, we design this trial to examine the feasibil-
ity and effectiveness of GOH for knee OA management
in the context of a routine clinical care. We hypothesize
that GOHT can serve as a convenient telemedicine
platform providing disease-enhanced management for
OA patients.
Methods/design
Trial design
This study is a prospective, parallel randomized controlled
trial (RCT) conforming to Standard Protocol Items: Rec-
ommendations for Interventional Trials (SPIRIT) guide-
lines (Additional file 1) [15]. The flow chart of the
participants is illustrated in Fig. 1. This study will be car-
ried out in our hospital (Fig. 2). The total duration of the
study is expected to take approximately 12 months de-
pending on the process of enrollment and follow-up visits.
Both groups will be followed up for 6 months.
Participants
Inclusion criteria
Participants will be qualified for inclusion when they
meet the following criteria: meeting the 1986 American
College of Rheumatology (ACR) classification criteria for
knee OA [16]; knee OA with a pain score of at least
20 mm on a 100-mm Visual Analogue Scale (VAS) for at
least 6 months [17]; Kellgren and Lawrence grades 0–3
[18]; age 50 to 75 years on the date of invitation to partici-
pate; availability of GOHT platforms in the community;
ability to communicate and to understand the study.
Exclusion criteria
Participants will be excluded if they have any of the fol-
lowing conditions: OA with severe joint deformity which
needs surgery; other joint diseases, including rheumatoid
arthritis and joint trauma; autoimmune diseases; chronic
digestive disorders including chronic gastritis and chronic
hepatitis; stroke; chronic kidney diseases; cancers; de-
mentia or substantial cognitive impairment; psychotic
illness; inability to give informed consent; unable to
communicate or to understand the study; and no access
to a GOHT platform.
Recruitment
First, we will set up a research team, including rheuma-
tologists, orthopedists, clinical researchers and nurses.
Staff in the team are required to learn the details of the
trial well through workshops and group discussions. In
order to recruit participants, an invitation letter with a
brief introduction of the trial will be sent to outpatients
with knee OA. Advertising posters about the trial will
be placed in the local newspapers, homepage of the
hospital official website and WeChat (a popular social
media application in China) official account. An over-
view of the trial and various announcements will also
be available on these platforms. In the clinic, clinicians
will be responsible for identifying the potential partici-
pants from the outpatients’ reception room, and will
further make an overall assessment to decide whether
they meet the requirements. Participants who meet the
eligibility criteria will be recruited from February 2018
to June 2018.
Sample size
This pilot study will be conducted without performing a
formal sample size calculation, as the primary outcome
is the feasibility of GOHT in the enhanced management
for patients with OA. We plan to recruit 20 participants
for each group, allowing for a 20% dropout over the
period. As the recommended sample size for a feasibility
pilot trial is 12 per group [19], we anticipate that the
sample size of 40 participants will provide us with suffi-
cient information about the feasibility of the intervention
including the enrollment rate and the acceptability of
the intervention.
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Randomization and blinding
Recruited participants will be randomly allocated to either
the CT-GOHT group (intervention) or the CT group
(control) at a 1:1 ratio. Random numbers will be generated
using a computer software program run by an external
statistician. Each of the random numbers with the group
assignment will be written on a piece of paper and packed
in a sealed envelope. After baseline assessment, partici-
pants will be provided an envelope according to the
randomization sequence. The outcome assessors will be
blinded to the participant randomization assignment.
Intervention group (CT-GOHT group)
In addition to conventional therapy (celecoxib, 0.2 g daily),
participants in the CT-GOHT group will receive a brief
repeated GOH-based management every month via the
GOHT platform. The web-based management is expected
to last 20–30 min for an independent intervention, contain-
ing three broad segments: encouragement, educational
lectures and medical issues. The clinicians who perform the
intervention have received standardized training and should
be familiar with the process and the detailed contents of an
intervention. To ensure standardized interventions for each
Fig. 2 The operating mode of Guangdong Online Hospital (GOH)
Fig. 1 Flow chart of trial participation
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participant, standard operating procedures will be provided
for the researches.
Participants will be required to attend follow-up clinics
at 2 weeks, 3 months and 6 months after the initiation
of the trial. When the symptoms get worse, participants
will be allowed to get further treatment at any time.
Encouragement
This session aims to comfort patients and help them to
face illness with great courage. The participants will be
allowed to express their negative feelings related to OA.
The clinician will encourage them to be optimistic and,
to make them feel that they are being cared for and
listened to.
Educational lectures
In this session, the participants will receive background
knowledge of OA, including pathogenesis, risk factors, clin-
ical manifestations, pharmacological therapies and progno-
sis of OA. Besides, some feasible non-pharmacological
therapies, like dietary control, weight loss and proper exer-
cise, will be recommended to the participants based on
their personal conditions. The importance of long-term
disease management in the rehabilitation of OA will also be
emphasized. If there are any questions related to knee OA
or the study, the participants are expected to receive
responses from the clinician via GOH.
Medications
The clinician will emphasize the importance of medica-
tions in disease remission and remind participants to
take medications on time at each GOHT visit. Besides,
the clinician will tell participants the potential side
effects medications may cause. If possible severe adverse
reactions emerge, the participants should withdraw from
the trial and get further treatments.
Control group
Participants in the CT group will receive conventional
therapies (celecoxib, 0.2 g daily). They will not receive
any network-enhanced management via GOH. Similarly,
participants will be required to attend follow-up clinics
at 2 weeks, 3 months, 6 months after the initiation of
therapy. Participants will be allowed to receive further
treatments when their symptoms get worse. Any add-
itional treatments received during the follow-up period
will be recorded.
Participants in both groups are free to withdraw from
the study at any time, but the withdrawal rates and rea-
sons will be recorded.
Outcome assessments
The outcome assessments will be made at baseline,
2 weeks and 3 month later after the initiation of the
study and at the end of 6 months. All measurements of
participants will be performed by a researcher blinded to
the group allocation.
Primary outcome measures
The primary outcome measurement is feasibility of the
study. It will be evaluated by recording the proportion of
patients with knee OA who meet eligibility criteria but
decline to participate; the adherence to the intervention
and the withdrawal rates. Besides, we will investigate the
satisfaction in using GOHT among participants in the
CT-GOHT group (Fig. 3).
Secondary outcome measures
The Western Ontario and McMaster Universities Osteo-
arthritis Index (WOMAC) [20] will be used to measure
pain, stiffness and physical function in the knee. WOMAC,
a self-administered health-status instrument for patients
with knee OA, consists of 24 items within three subscales:
pain (five items), stiffness (two items) and physical function
(17 items). We will be use the VAS to measure the items of
pain. The WOMAC scores will be standardized to a 0
(worst) to 100 (best) total score range.
The Multidimensional Fatigue Inventory (MFI) [21] will
be used to evaluate fatigue. The MFI, widely used for meas-
uring fatigue, is a 20-item self-report instrument. It covers
the following dimensions: general fatigue, physical fatigue,
reduced activity, reduced motivation and mental fatigue.
The Hospital Anxiety and Depression Scale (HADS)
[22] will be used to assess anxiety and depression. The
HADS is a widely used instrument to measure mental
condition in many chronic diseases. It is a 14-item scale
with seven items for anxiety (HADS-A) and seven for
depression (HADS-D). Scores ranged from 0 to 21 for
each subscale.
The Pittsburgh Sleep Quality Index (PSQI) [23] will be
used to assess sleep quality. The PSQI, Global PSQI with
a total score ranging from 0 to 21, is a standardized self-
administered questionnaire for the assessment of sleep
quality over the previous 1 month. It contains several
sections to assess subjective sleep quality, sleep latency,
sleep duration, sleep efficiency, sleep disturbances, use
of sleeping medications and daytime dysfunctions.
Ethics
This trial has been approved by the Human Research Ethics
Committees of Guangdong Second Provincial General
Hospital (2017-FS-032). This trial has been registered at
the Chinese Clinical Trials Registry: ChiCTR1800014465.
All study participants will be provided with written con-
sents prior to participation. Written informed consent has
been obtained from the patients for publication of this
manuscript and accompanying images. All study-related
information will be securely protected at the study site.
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Quality assurance and monitoring
To ensure that the study is of a high quality, all study pro-
cedures will be conducted in compliance with the protocol
in the principles of the Good Clinical Practice (GCP) pro-
vided by the International Conference on Harmonization
[24]. The researchers will learn to perform the study prop-
erly via a 2-day training workshop. They will also be given a
written protocol and standardized intervention content
documents. A detailed explanation of the study and a task
form (Fig 4) will be provided to participants. Moreover, the
outcome assessors will be blinded to group assignment.
The study progress and research data will be consist-
ently monitored by an Independent Data Monitoring
Board (IDMB), which will be independent from the
study organizers. The IDMB will examine trial proce-
dures, facilitate compliance with the study protocol, and
ensure the data quality and safety.
Withdrawal
Participants are free to withdraw from the study at any
time, which will be informed during the consent process.
If a participant chooses to withdraw, they will be asked
to provide reasons and the reasons for withdrawal will
be recorded. Besides, participants can discontinue the
study at any time point if they experience any adverse
events. The adverse events will be recorded.
Planned statistical analysis
To evaluate the feasibility of the study, we will calcu-
late the proportion of enrolled participants out of all
eligible patients, participants who adhered to the
intervention and the dropout rates. Besides, a patient
satisfaction survey for the use of GOHT will be col-
lected and analyzed.
Means and standard deviations will be used to describe
between-group statistics of WOMAC, MFI, HADS and
PSQI. All these variables will be analyzed using a
repeated-measures mixed-effect model with terms for age,
sex, Body Mass Index and treatments. The measurement
data will be assessed for normal distribution using
Shapiro-Wilk’s test for both groups. Independent samples’
t test will be used for the comparison of two-independent
samples. Non-parametric tests (Mann-Whitney U test)
will be used in cases of abnormal distribution. Statistical
analysis will be processed by SPSS software (version 19.0).
The categorical variables will be compared by a chi-square
test. P < 0.05 will be accepted as the threshold for statis-
tical significance.
Fig. 3 The satisfaction survey of Guangdong Online Hospital (GOH)
Fig. 4 Task form for the conventional therapy plus a brief
Guangdong Online Hospital intervention (CT-GOH) group (above)
and the conventional therapy (CT) group (below)
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Discussion
Long-term disease management combined with both
pharmacological and non-pharmacological therapies is
essential for the treatment of chronic diseases. As a kind
of long-term chronic disease management, telemedicine
has shown effectiveness in the treatment of OA by pro-
viding multi-faceted interventions [25]. However, a con-
siderable number of OA patients in China are unlikely
to receive long-term treatment due to poor adherence,
drug resistance or lack of disease knowledge. Further-
more, China is a large country with regional imbalance
in economic development, which makes it difficult for
patients from the remote areas to receive high-quality
medical services. Recently, the Chinese Government has
put forward a series of policies including the “Internet
Plus” action plan to deal with this situation [26, 27].
This study is an exploratory trial in response to the
Internet Plus action plan by providing disease manage-
ment via GOHT. It will reveal the willingness of patients
to participate in the forthcoming RCT, adherence to the
interventions and the possible dropout rates. In addition,
this study will collect preliminary information regarding
the effects of GOHT in relieving knee pain, stiffness and
physical dysfunction, in improving fatigue, anxiety,
depression and sleep quality in patients with knee OA.
These will be useful for power calculations in future
larger-scale RCTs. The potential limitation is that the
participants may not turn up on time for clinic visits
and GOHT visits during this 6-month study. Therefore,
every participant will be provided with a task form with
the accurate time of their appointments stated. The
schedule of enrollment, interventions, and assessments
is explained in Fig. 5.
To the best of our knowledge, this is the first trial to
explore the role of telemedicine in the management of
OA patients in China. The findings from this study
will contribute to better understanding of the practice
of telemedicine in China. As a part of the Internet
Plus action plan, our study has been encouraged by
the provincial government and GOH is likely to pro-
vide telemedicine services for patients with other
chronic diseases and help them with their health prob-
lems via a web-based disease management program. If
GOH is feasible and effective in disease-enhanced
STUDY PERIOD
Enrolment Allocation Post-allocation Close-out
TIMEPOINT -t1 0 6-month tx
ENROLMENT:
Eligibility screen X
Informed consent X
Sample size 
calculation X
Allocation X
INTERVENTIONS:
CT-GOHT group
Control group
ASSESSMENTS: Baseline Week 2
Month 
3 Month 6
Feasibility X X
WOMAC X X X X
MFI X X X X
HADS X X X X
PSQI
X X X X
Fig. 5 The schedule of enrollment, interventions, and assessments
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management for patients with knee OA, a further
larger-scale clinical trial will be conducted to test the
effect of GOHT telemedicine on OA. This will eventu-
ally be beneficial for OA patients, especially for those
in remote areas.
Trial status
The trial is still pending at the time of manuscript
submission.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents*. (DOC 120 kb)
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